Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acadia Pharmaceuticals will announce its first quarter financial results on May 8, 2023, after market close. A conference call and webcast will occur on the same day at 4:30 p.m. Eastern Time for discussing these results and company operations. The call will be available on Acadia's website and archived until June 7, 2023. Acadia is recognized for its innovative therapies in neuroscience, particularly for conditions like Parkinson’s disease psychosis and Rett syndrome. The company continues to focus on developing solutions for negative symptoms of schizophrenia and Alzheimer’s-related issues. Investors should note that forward-looking statements regarding future events may contain risks and uncertainties that could affect actual results.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the presentation of four posters at the American Academy of Neurology (AAN) annual meeting from April 22 to 27, 2023, in Boston, Mass. The posters include a secondary analysis of communication-related endpoints from the Phase 3 LAVENDER™ study and an interim analysis of the DAFFODIL™ study. Notable presentations involve real-world physician surveys and an analysis of healthcare resource utilization in Rett syndrome patients. The poster P13 highlights the benefits of Trofinetide compared to placebo in communication abilities among individuals with Rett syndrome, thus showcasing the drug's potential. Rett syndrome is a rare neurological disorder affecting approximately 6,000 to 9,000 patients in the U.S., with Trofinetide being a key treatment option.
Acadia Pharmaceuticals has launched DAYBUE (trofinetide), the first FDA-approved therapy for Rett syndrome, a neurodevelopmental disorder affecting 6,000 to 9,000 patients in the U.S. The drug is available for individuals aged two and older and was officially approved on March 10, 2023. The company emphasizes its commitment to patient support, expanding the Acadia Connect program to enable access to this therapy through financial assistance and prescription support. Notable endorsements from healthcare professionals highlight DAYBUE's potential to improve symptoms and enhance patients' quality of life.
Common side effects include diarrhea (experienced by 85% of patients) and weight loss (12% had losses exceeding 7%). Acadia continues to focus on treatments addressing unmet medical needs in the field of neuroscience.